$PTIX

Protagenic Therapeutics, Inc.\new

No enriched coverage for $PTIX in the last 7 days.

$31K
ARMEN GARO H
0%
See all $PTIX insider activity →
Low

ARMEN GARO H purchased $13K of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 20,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.65 on 2026-08-21.

ARMEN GARO H purchased $10K of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 16,634 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.59 on 2026-08-20.

ARMEN GARO H purchased $945 of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 2,700 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.35 on 2026-08-19.

PTIX sentiment & insider activity

Recent PTIX coverage spans insider activity, regulation and financial news.

In the last 30 days, PTIX insiders filed 7 SEC Form 4 transactions — 7 purchases ($31K) and no sales. The most active reporter was ARMEN GARO H, EXEC. CHAIR & PRINCIPAL OFF, with 6 filings.

What's driving PTIX

alphai scores every news story that mentions PTIX with an AI model for sentiment and relevance, and aggregates insider trades from Protagenic Therapeutics, Inc.\new's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PTIX

Score
$PTIXMedAI 8/10

Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder

Protagenic Therapeutics (PTIX) received FDA feedback supporting its planned Phase 1 program for PT00114, a treatment for generalized anxiety disorder. The FDA raised no objections to the program design, dose-escalation approach, or CMC and nonclinical packages. The company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027. PT00114 has shown promising results in preclinical and early-phase studies.

Monday’s insider activity: Notable buys and sells disclosed

Investing.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.

$PTIXMed

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY

^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

Related tickers